Policy & Medicine

Sanofi Awarded Attorney Fees in “Frivolous” False Claims Act Suit

Thomas Sullivan May 17, 2021 0

Some readers may remember the False Claims Act lawsuit filed by Amphastar Pharmaceuticals Inc. (Amphastar) against Sanofi-Aventis, S.A. (Sanofi), alleging that Lovenox – a blood thinner – was improperly patented and that Sanofi “obtained an illegal monopoly over a drug and then knowingly overcharged the United States.” In July 2015, California…

When Money and Doritos Don’t Suffice – The…

Thomas Sullivan Oct 12, 2019 0

The Chaos Over Drug Compounding Continues As Judge Throws…

Thomas Sullivan Sep 17, 2019 0

Sanofi Awarded Attorney Fees in “Frivolous” False Claims Act…

Some readers may remember the False Claims Act lawsuit filed by Amphastar Pharmaceuticals Inc. (Amphastar) against Sanofi-Aventis, S.A. (Sanofi), alleging that Lovenox – a blood thinner – was…

CMS Announces Changes to Part D Payment Modernization Model

The Biden administration has walked back a last-minute bid by its predecessor to give Medicare Part D plans the ability to restrict access to certain classes of drugs such as antidepressants. The…

ACPE Offers Resources to Support Transition to ACCME Standards

The Accreditation Council for Pharmacy Education recently added tools and resources to its website to support the new Accreditation Council for Continuing Medical Education (ACCME) Standards for…

HHS Releases New Buprenorphine Practice Guidelines

Recently, the United States Department of Health and Human Services (HHS) released new buprenorphine practice guidelines, Practice Guidelines for the Administration of Buprenorphine for Treating…

Six Individuals Sentenced for Their Roles in Anti-Kickback and…

Six individuals were recently sentenced for their connection to multiple health care fraud conspiracies involving kickbacks and fraudulent billings that resulted in almost $8 million in losses to…

DOJ Announces $12.6 Million Settlement with Incyte Corporation

On May 4, 2021, the United States Department of Justice announced a $12.6 million settlement with Incyte Corporation, resolving allegations that Incyte violated the False Claims Act by using a…

Bristol-Myers Squibb Pays $75 Million to Resolve False Claims…

Bristol-Myers Squibb (BMS) recently came to an agreement with the United States and participating states to pay $75 million plus interest to resolve False Claims Act allegations. According to the…

What Does Secretary Becerra Mean for Drug Prices?

In March, the U.S. Senate voted to confirm Xavier Becerra as secretary of the Department of Health and Human Services despite nearly unanimous opposition from Republicans. The near party-line vote was…

Pacira Files Libel Lawsuit Against the American Society of…

Pacira Biosciences has filed a libel lawsuit against the American Society of Anesthesiologists (ASA) and other defendants seeking pecuniary damages and the retraction of three articles published in…

HHS Releases Notice of Benefit and Payment Parameters for 2022,…

Recently, the United States Department of Health and Human Services (HHS) released the Notice of Benefit and Payment Parameters for 2022 final rule, part two (scheduled to be published on May 5,…

House of Representatives Reintroduces Focus on Drug Prices

On April 22, 2021, leadership from the United States House of Representatives reintroduced H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. The legislation aims to lower the cost of…

Transparency & Aggregate Spend: Virtual Event

From May 18, 2021 to May 20, 2021, the Transparency & Aggregate Spend will take place as a virtual event. The program aims to help attendees ensure compliance in a complex, ever-evolving…